Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Expected to Yield Notable Results in Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs. “Lexaria [recently] announced that the study program DIAB-A22-1 [had begun] on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (‘CBD’) may potentially have therapeutic utility against diabetes,” a recent article reads. “Lexaria is optimistic that its DehydraTECH-CBD will yield notable results from this study, especially having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study. There is a strong connection between heart disease, hypertension and diabetes, with hypertension proving to be as frequent in people with diabetes and hypertensive patients being at a greater risk of developing diabetes. So far, CBD has shown some ability to reduce the incidence of diabetes in mice, with the study yielding a significant decrease in pancreatic islets production of destructive insulitis and inflammatory cytokine production. Lexaria looks to build on these findings and investigate whether its patented DehydraTECH-CBD may potentially have therapeutic utility against diabetes.”

To view the full article, visit

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.